{"nct_id": "NCT05754684", "age": "Adults", "cancer_center_accrual_goal_upper": 0, "data_table4": "Interventional", "drug_list": {"drug": [{"drug_name": "Drug: Interleukin-2"}, {"drug_name": "Drug: Granulocyte-Macrophage Colony-Stimulating Factor"}, {"drug_name": "Drug: Dinutuximab beta"}, {"drug_name": "Drug: Spironolactone"}, {"drug_name": "Drug: Naxitamab"}, {"drug_name": "Biological: Natural killer cell"}]}, "long_title": "Quadruple Immunotherapy for Paediatric Patients with Relapsed or Refractory Neuroblastoma", "management_group_list": {"management_group": [{"is_primary": "Y", "management_group_name": "Group1"}]}, "oncology_group_list": {"oncology_group": [{"group_name": "Group1", "is_primary": "N"}]}, "phase": "PHASE2", "principal_investigator": "", "principal_investigator_institution": "Hong Kong Children's Hospital", "program_area_list": {"program_area": [{"is_primary": "Y", "program_area_name": "Program1"}]}, "protocol_id": 0, "protocol_no": "", "protocol_target_accrual": 29, "protocol_type": "INTERVENTIONAL", "prior_treatment_requirements": ["Inclusion Criteria:", "* relapsed or refractory neuroblastoma", "* Adequate organ function: creatinine clearance \u226540 ml/min/1.73m2, total bilirubin \u22643 times upper limit of normal and ALT \u2264500 IU/L, left ventricular shortening fraction \u226525%, and oxygen saturation \u226592% in room air", "* Karnofsky or Lansky performance status score \u226550", "* Has an appropriate HLA-haploidentical NK-cell donor available", "Exclude - Exclusion Criteria:", "Exclude - * Pregnant or lactating woman", "Exclude - * HIV infection", "Exclude - * Patients for whom conventional treatment is deemed more appropriate", "Exclude - * Patients who are unlikely to benefit, e.g., terminal malignancy with life expectancy \\<1 month"], "short_title": "Quadruple Immunotherapy for Neuroblastoma", "site_list": {"site": []}, "sponsor_list": {"sponsor": [{"is_principal_sponsor": "Y", "sponsor_name": "Hong Kong Children's Hospital", "sponsor_protocol_no": "", "sponsor_roles": "sponsor"}]}, "staff_list": {"protocol_staff": []}, "status": "open to accrual", "summary": "This is a single-arm clinical trial to evaluate the efficacy and safety of quadruple immunotherapy with natural killer (NK) cells, anti-GD2 antibody, cytokines (interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF)) and retinoid X receptor gamma (RXRg) agonist spironolactone for paediatric patients with relapsed or refractory neuroblastoma.", "treatment_list": {"step": [{"arm": [{"arm_code": "Intervention", "arm_internal_id": 0, "arm_description": "Quadruple immunotherapy", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Biological: Natural killer cell", "level_internal_id": 0, "level_suspended": "N"}, {"level_code": "1", "level_description": "Drug: Dinutuximab beta", "level_internal_id": 1, "level_suspended": "N"}, {"level_code": "2", "level_description": "Drug: Interleukin-2", "level_internal_id": 2, "level_suspended": "N"}, {"level_code": "3", "level_description": "Drug: Granulocyte-Macrophage Colony-Stimulating Factor", "level_internal_id": 3, "level_suspended": "N"}, {"level_code": "4", "level_description": "Drug: Spironolactone", "level_internal_id": 4, "level_suspended": "N"}, {"level_code": "5", "level_description": "Drug: Naxitamab", "level_internal_id": 5, "level_suspended": "N"}]}], "match": [{"and": [{"clinical": {"oncotree_primary_diagnosis": "", "disease_status": ["", ""]}}, {"genomic": {"hugo_symbol": "", "variant_category": ""}}]}]}]}}